uso de inhibidores de la bomba de

123 Clarke R, Derry S, Moore RA, McQuay HJ. Single dose oral etoriinhibidores de COX-2 for acutepostoperative pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.:CD004309. DOI: 10.1002/14651858.CD004309.pub2.124 Derry S, Barden J, McQuay HJ, Moore RA. Single dose oral celecoxib for acute postoperative pain inadults. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD004233. DOI:10.1002/14651858.CD004233.pub2.125 Malmstrom K, Daniels S, Kotey P, Seidenburg BC, Desjardins PJ. Comparison of rofecoxib andcelecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomised, placebo- andactive-comparator-controlled clinical trial. Clinical Therapeutics. 1999;21(10):1653-63.126 Cheung R, Krishnaswami S, Kowalski K. Analgesic efficacy of celecoxib in postoperative oral surgerypain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study. ClinicalTherapeutics. 2007;29(Suppl):2498-510.127 Roy YM, Derry S, Moore RA. Single dose oral lumiracoxib for postoperative pain in adults. CochraneDatabase of Systematic Reviews 2010, Issue 7. Art. No.: CD006865. DOI:10.1002/14651858.CD006865.pub2.128 Zelenakas K, Fricke JR Jr, Jayawardene S, Kellstein D. Analgesic efficacy of single oral doses oflumiracoxib and ibuprofen in patients with postoperative dental pain. International Journal of ClinicalPractice. 2004; 58(3):251-6.129 Massey T, Derry S, Moore RA, McQuay HJ. Topical NSAIDs for acute pain in adults. CochraneDatabase of Systematic Reviews 2010, Issue 6. Art. No.: CD007402. DOI:10.1002/14651858.CD007402.pub2. Disponible en:http://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD007402/frame.html (consultado 9-3-2011).130 Simon, LS, Hatoum, TH, Bittman, RM, et al. Risk factors for serious nonsteroidal-inducedgastrointestinal complications: Regression analysis of the MUCOSA trial. Fam Med. 1996; 28:202.131 Gastroprotection with NSAID: do we follow guideliness? Bandolier. December 2006; 154-8.132 Weideman, RA, Kelly, KC, Kazi, S, et al. Risks of clinically significant upper gastrointestinal eventswith etodolac and naproxen: a historical cohort analysis. Gastroenterology. 2004; 127 :1322.133 Bhatt, DL, Scheiman, J, Abraham, NS, et al. ACCF/ACG/AHA 2008 Expert Consensus Document onReducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. Am J Gastroenterol. 2008;103:2890.134 Targownik LE, Metge CJ, Leung S, Chateau DG. The relative efficacies of gastroprotective strategiesin chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134(4):937-44.135 Hur C, Chan A T, Tramontano A C, Gazelle G S. Coxibs versus combination NSAID and PPI therapyfor chronic pain: an exploration of the risks, benefits, and costs. Ann Pharmacother. 2006; 40(6): 1052-1063. Disponible en : http://www.theannals.com/cgi/content/full/40/6/1052 (consultado 8-3-2011)136 Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, et al. Celecoxib versus diclofenac andomeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med.2002;347(26):2104-10.137 Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG. Video capsule endoscopy toprospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. ClinGastroenterol Hepatol. 2005;3:133-41.138 Latimer N, Lord J, Grant RL, O’Mahony R, Dickson J, Conaghan PG. Cost effectiveness of COX 2selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for102